濮阳东方医院看阳痿价格收费透明濮阳东方医院男科看早泄价格合理,濮阳东方医院男科治病贵不,濮阳东方医院治疗早泄很正规,濮阳东方看妇科评价很好,濮阳东方医院收费高不高,濮阳东方男科医院割包皮口碑很好,濮阳东方医院割包皮价格合理

SAN FRANCISCO, Nov. 21 (Xinhua) -- Hewlett-Packard Co. (HP) on Monday reported that its profit in the most recent quarter fell more than 90 percent with sales also declining.In the company's fourth quarter of fiscal 2011 ended Oct. 31, the company posted net earnings of 239 million U.S. dollars, compared with 2.54 billion dollars in the same period a year earlier.HP's net revenue for the quarter reached 32.1 billion dollars, down 3 percent year-on-year.Excluding one-time items, HP earned 1.17 dollars per share, which topped estimates of analysts.According to Thomson Reuters, analysts had expected earnings of 1.13 dollars per share on revenue of 32.05 billion dollars.It was the first earnings report since Meg Whitman took over as chief executive officer (CEO) of the information technology giant on Sept. 22, replacing Leo Apotheker."HP has a great opportunity to build on our strong hardware, software, and services franchises with leading market positions, customer relationships, and intellectual property," Whitman said in a statement after the earnings announcement."We need to get back to the business fundamentals in fiscal 2012, including making prudent investments in the business and driving more consistent execution," she added.

BEIJING, Dec. 2 (Xinhua) -- Medical experts and leaders from the world's leading orthopaedic societies on Friday called for the improvement of health insurance programs and medical care for people in developing countries."Health care should reach the unreached," said Professor H.K.T. Raza, president of the Asia Pacific Orthopaedic Association (APOP), at the Sixth International Congress of Chinese Orthopaedic Association (COA), which is running from Thursday to Sunday in Beijing."If we really want to improve people's well-being, we have to make health care available to those who have difficulty accessing it. Although that will probably be a very difficult task, we should try and do it gradually," said Professor K.M. Chan from the Prince of Wales Hospital in Hong Kong.Statistics from the Ministry of Health show that 1.27 billion Chinese, or 95 percent of the country's population, are covered by basic medical insurance programs.However, private medical insurance accounts for less than 2 percent of the country's health care financing, while private insurance in other countries stands at an average of 20 percent."With the increasing demand for quality health care, there will be higher demand for commercial insurance. With more private health funding in the system, we can increase the quality," Prof. Chan said.Government health care expenditures should be directed toward those who can't afford health care at all, while commercial insurance should cover the needs of those who can afford to purchase it, Prof. Chan said."We need to have different approaches combined together to revamp the current health insurance structure in China," he said."If you want to raise the quality of health care, you need to have the responsibility from the government, the individuals and the insurance system," he added.While China may need to promote its commercial health insurance, in India, the situation is different. Though many medical tourists choose India as their destination for affordable care, health insurance is uncommon in the country.While patients typically pay out of their own pockets for routine care, it is estimated that over 300 million Indians out of a population of 1.2 billion still live on less than one U.S. dollar per day.

WASHINGTON, Nov. 7 (Xinhua) -- U.S. researchers have demonstrated for the first time that the brain is a key player in regulating glucose (sugar) metabolism in humans.The findings, published Monday in the online edition of the Journal of Clinical Investigation, suggest that drugs targeting the brain and central nervous system could be a novel approach to treating diabetes."The brain is the body's only organ that needs a constant supply of glucose to survive, so it makes sense that it would have some say over how much glucose is produced," said study leader Meredith Hawkins, professor of medicine and director of the Global Diabetes Initiative at Yeshiva University, in a statement. "This role for the brain was demonstrated in earlier studies in rodents, but there was considerable controversy over whether the results could be applied to humans. We hope this study helps to settle the matter."In an earlier study in rodents, researchers showed that activation of potassium channels in the brain's hypothalamus sends signals to the liver that dampen its production of glucose. Those findings, published in Nature in 2005, challenged the conventional thinking that blood sugar production by the liver (the body's glucose factory) is regulated only by the pancreas (which makes insulin to metabolize glucose). But carefully performed studies on dogs, conducted at Vanderbilt University, failed to replicate the results, suggesting the Einstein findings in rodents might not be relevant to higher mammals, including humans.The current study, involving people, was aimed at resolving this controversy. Ten nondiabetic subjects were given oral diazoxide, a drug that activates potassium channels in the hypothalamus. (The drug is not used to treat diabetes.) Hormone secretion by the pancreas was controlled to ensure that any change in sugar production would only have occurred through the drug's effect on the brain. After the researchers administered the drug, blood tests revealed that patients' livers were producing significantly less glucose than before.Hawkins and her team then repeated this in rats, again giving diazoxide orally, achieving similar results. They confirmed that sufficient amounts of diazoxide crossed the blood-brain barrier to affect potassium channels in the hypothalamus. Additional experiments confirmed that diazoxide was working through the brain. Specifically, the researchers were able to completely block the effects of diazoxide by infusing a specific potassium channel blocker directly into the brain."This study confirms that the brain plays a significant role in regulating glucose production by the liver," said lead author Preeti Kishore, assistant professor of medicine. "We are now investigating whether this 'brain-to-liver' pathway is impaired in people with diabetes. If so, we may be able to restore normal glucose regulation by targeting potassium channels in the brain."

PARIS, Dec. 23 (Xinhua) -- French health authorities on Friday urged 30,000 women to remove the local-made breast implant, pledging that relevant expenses would be covered by the state.The health ministry said in a statement that they spot "no increased risk of cancer currently in women wearing the PIP (Poly Implant Prothese) brand compared with other implants.""However, well-established risks associated with these prostheses are rupture and irritant gel may lead to inflammatory reactions, making it difficult to explant," the statement added.French Health Minister Xavier Bertrand advised French women who have the PIP implants to get them taken out "as a preventive measure but not of an urgent nature." The removal of the implant will be at the state's expense.The recommendation came after eight cases, mainly breast cancer, were reported recently among women with PIP implants.The involved implant was produced by the French company PIP, once the world's third-largest producer of silicone implants who sold its products to tens of thousands of women in more than 65 countries, mainly in South America and western Europe.

SEOUL, Nov. 8 (Xinhua) -- Samsung Electronics, the world's largest flat screen TV vendor, said Tuesday that it has suspended its plan to develop active shutter three-dimensional (3D) TVs with RealD, the U.S.-based 3D technology supplier."Samsung has decided to focus on our own initiatives of 3D technology, and continues to research and develop next-generation 3D display technologies, including a glasses-free 3D solution for the home," the tech firm said in an e-mailed statement.The active shutter 3D technology drew public attention after Samsung reached a deal with RealD earlier this year to jointly develop such technology, aiming to unveil 3D TVs based on the technology early next year.The active shutter is a next generation 3D technology that incorporates merits from both shutter-glass (SG) technology, which Samsung adopted, and film patterned retarder (FPR) technology, which LG introduced in December last year.The SG technology has been touted as better picture quality and deeper 3D images, but the eyewear is heavier because it requires batteries and chips to work. The active shutter 3D technology moved its function of 3D image creation from eyewear to flat panel, making the eyewear lighter.Despite the upgraded technology and its convenience, Samsung decided to focus on its existing SG technology as the global TV market is grappling with weak demand. The penetration rate, which gauges the ratio of 3D sets against the total flat screen TVs, was expected to rise to 9.9 percent by year-end from the 3 percent a year earlier, according to Woori Investment & Securities, a local securities firm.